(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

General procedure for the synthesis of B. by Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”